acquired
Stage
About
Immune Design developed in vivo vaccine and therapeutic platforms to activate antigen-specific cytotoxic immune responses targeting cancer and infectious diseases, and was acquired by Merck in 2019.
Explore Immune Design's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.